)
Visual
test
Chugai Pharmaceutical
Chugai Pharmaceutical (4519) investor relations material
Chugai Pharmaceutical Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary29 Jan, 2026
Executive summary
Achieved record-high revenue, operating profit, and net income for FY2025, with revenue at JPY 1,257.9 billion (+7.5% YoY), core operating profit at JPY 623.2 billion (+12.1% YoY), and net income at JPY 451.0 billion (+13.6% YoY); operating margin reached 49.5%.
Growth was driven by strong exports of Actemra and Hemlibra, robust domestic sales, increased royalty income, and new product launches.
Management focused on strengthening R&D, accelerating open innovation, and advancing digital transformation, including AI-driven business transformation.
Opened a U.S. partnering office to enhance global innovation and collaboration.
Special dividends were paid for the 100th anniversary, resulting in a high payout ratio for 2025.
Financial highlights
Revenue: JPY 1,257.9 billion (+7.5% YoY); core operating profit: JPY 623.2 billion (+12.1% YoY); net income: JPY 451.0 billion (+13.6% YoY); EPS: JPY 274.02 (+13.6% YoY).
Domestic sales: JPY 472.4 billion (+2.5% YoY); overseas sales: JPY 605.4 billion (+12.8% YoY); other revenues, including royalties, rose to JPY 180.1 billion.
Cost to sales ratio improved to 32.6% in 2025; R&D expenses increased to JPY 180.1 billion (+1.8% YoY).
Operating profit margin reached a record 49.5%, up 2 percentage points year-on-year.
Positive foreign exchange impact added JPY 49.6 billion to revenue and JPY 44.2 billion to operating profit.
Outlook and guidance
FY2026 revenue forecast: JPY 1,345 billion (+6.9% YoY); core operating profit: JPY 670 billion (+7.5% YoY); core net income: JPY 485.0 billion (+7.5% YoY); core EPS: JPY 295.00 (+7.7% YoY).
Domestic product sales expected to rise by JPY 25.6 billion, offsetting NHI price revisions and generic competition; overseas sales to remain flat.
Dividend for 2025 set at JPY 272 per share (including 100th anniversary dividend); 2026 dividend forecast at JPY 132 per share, with a stable 45% payout ratio.
Strategic focus on accelerating R&D, digital transformation, and global product launches to achieve sustainable growth.
Giredestrant: new standard of care potential?
Orforglipron's impact on 2026 other revenues?
US partnering office: expected R&D impact?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
Next Chugai Pharmaceutical earnings date
Q1 202624 Apr, 2026
Chugai Pharmaceutical
Next Chugai Pharmaceutical earnings date
Q1 202624 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Chugai Pharmaceutical Co., Ltd., operating under the umbrella of F. Hoffmann-La Roche Ltd, is a notable player in the pharmaceutical industry, mainly in Japan. Chugai is dedicated to the research, development, commercialization, and manufacture of biopharmaceuticals and therapeutic antibodies. The company's product range focuses on several therapeutic areas such as cancer, bone and joint diseases, renal diseases, and immune disorders, among others. It also plays a significant role in the global healthcare market through its international operations in North America, Europe, and other regions in Asia. Chugai Pharmaceutical is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage